Kiniksa Pharmaceuticals, Ltd.

KNSA· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$77.24-2.63%

2026-09-18

Financials

Valuation Metrics

Kiniksa Pharmaceuticals, Ltd.'s Market Cap is $5.94B. At end of 2025 it was $3.06B. Ranked #1210 of 3,121 in US market (top 39%), #402 of 1,463 on NASDAQ (top 27%), #67 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 25%) by Market Cap.

Investment Metrics(as of 2026-09-18)

Metric	Value	Rank
Size
Market Cap	$5.94B	US#1,210/3,121 Sec#67/266
Revenue	$841M	US#1,974/3,121 Sec#57/266
Net Income	$81M	US#1,711/3,121 Sec#55/266
Total Assets	$896M	US#2,528/3,121 Sec#111/266
Net Assets	$654M	US#2,063/3,121 Sec#90/266
Value
P/E	73.68x	US#2,039/3,121 Sec#60/266
P/B	9.08x	US#2,603/3,121 Sec#192/266
PEG	0.05x	US#123/3,121 Sec#8/266
P/S	7.07x	US#2,556/3,121 Sec#100/266
EV/EBITDA	51.53x	US#2,375/3,121 Sec#74/266
FCF Yield	3.08%	US#1,830/3,121 Sec#56/266
Profitability
ROE	12.33%	US#1,125/3,121 Sec#44/266
ROA	9.00%	US#556/3,121 Sec#39/266
Op. Margin	11.92%	US#1,441/3,121 Sec#56/266
Revenue Growth	58.85%	US#186/3,121 Sec#44/266
Earnings Growth	1583.88%	US#23/3,121 Sec#3/266
Financial Health
Debt Ratio	36.99%	US#426/3,121 Sec#123/266
Total Debt	$9M	US#2,846/3,121 Sec#203/266
FCF	$183M	US#1,436/3,121 Sec#47/266
Cash	$176M	US#1,830/3,121 Sec#124/266
Current Ratio	3.90x	US#596/3,121 Sec#166/266
Net Debt/EBITDA	-1.49x	US#229/3,121 Sec#16/266
Performance
1Y Return	115.03%	US#151/3,121 Sec#52/266
1M Return	-4.41%	US#967/3,121 Sec#94/266
From 52W High	-6.87%	US#255/3,121 Sec#20/266
1Y MDD	-21.12%	US#799/3,121 Sec#33/266
Trading
Volume	867,349 shares	US#2,084/3,121 Sec#218/266
Trading Value	$68M	US#1,495/3,121 Sec#117/266
Per Share
EPS	$1.05	US#1,662/3,121 Sec#46/266
BPS	$8.50	US#1,952/3,121 Sec#81/266